Compare PROP & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PROP | ELOX |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 52.5M |
| IPO Year | 2008 | 2013 |
| Metric | PROP | ELOX |
|---|---|---|
| Price | $0.31 | $12.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.50 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 1.2M | 19.0K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $85.81 | N/A |
| Revenue Next Year | $11.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.30 | $10.00 |
| 52 Week High | $2.55 | $23.40 |
| Indicator | PROP | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 33.03 |
| Support Level | N/A | N/A |
| Resistance Level | $0.44 | $14.65 |
| Average True Range (ATR) | 0.05 | 0.98 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 2.94 | 1.59 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.